Company intelligence / Profile preview

Complex Cargo

San Mateo, California, United Statescomplexcargo.com ↗

Ownership: Private
Development stage: Other

Overview

CARGO Therapeutics was developing next-generation, potentially curative CAR T-cell therapies with a focus on overcoming resistance and improving durability in hematologic cancers. Its lead autologous CD22-targeted product, firicabtagene autoleucel ("firi-cel", also known as CRG‑022), reached Phase II trials in large B-cell lymphoma patients who had failed prior CD19-directed therapies. In March 2025, the company discontinued its clinical programs—including the allogeneic platform—and reduced its workforce by ~90% while seeking strategic alternatives such as a reverse merger.

Therapeutic areas: OncologyHematology
Modalities: CAR-T cell therapyCell therapyGene-modified cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Complex Cargo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complex Cargo.

Explore the full profile